US STOCK
UTHR Stock Analysis
US stocks · market data · technical indicators
United Therapeutics Corporation
UTHRUS stocksQuote delayed 15 min
10/26 上午10:33 updated
$587.50
+2.71+0.46%
Open
$584.92
High
$590.98
Low
$576.24
Volume
63.82萬
UTHR price history
+21.00%Open
485.54
Latest
587.50
High
587.50
Low
481.47
Average
543.40
Advertisement
Financial snapshot
UTHR - United Therapeutics Corporation
EPS
27.92USD
Forward EPS
30.41USD
P/E
21.04x
Forward P/E
19.32x
P/B
3.92x
ROE
19.31%
ROA
11.61%
Operating margin
42.23%
Profit margin
41.56%
Revenue growth
-1.90%
Earnings growth
13.40%
Dividend yield
0.00%
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $783.30M | $781.50M | $790.20M | $799.50M | $798.60M |
| Gross profit | $683.80M | $648.10M | $686.80M | $698.60M | $711.00M |
| Operating income | $330.80M | $325.80M | $357.50M | $389.30M | $386.20M |
| Net income | $333.00M | $274.90M | $364.30M | $338.70M | $309.50M |
| Basic EPS | 7.82 | 6.32 | 8.41 | 7.73 | 6.86 |
| Diluted EPS | 7.27 | 5.82 | 7.70 | 7.16 | 6.41 |
Estimates vs actuals
Next earnings
2026-11-04
EPS estimate
6.36
Revenue estimate
$781.53M
Last surprise
+5.95%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-11-04 | 6.05 | Not reported | — |
| 2026-08-05 | 6.86 | 7.27 | +5.95% |
| 2026-05-06 | 6.86 | 5.82 | -15.13% |
| 2026-02-25 | 6.76 | 7.70 | +13.99% |
| 2025-10-29 | 6.96 | 7.16 | +2.86% |
| 2025-07-30 | 7.30 | 6.41 | -12.23% |
| 2025-04-30 | 6.54 | 6.63 | +1.30% |
| 2025-02-26 | 6.84 | 6.19 | -9.52% |
| 2024-10-30 | 7.12 | 7.07 | -0.68% |
| 2024-07-31 | 6.41 | 5.85 | -8.68% |
| 2024-05-01 | 5.59 | 6.17 | +10.31% |
| 2024-02-21 | 4.19 | 4.36 | +4.15% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| VANGUARD GROUP INC | 2025-12-31 | $2B | 0.03% |
| BlackRock Inc. | 2024-06-30 | $1.7B | 0.04% |
| STATE STREET CORP | 2026-06-30 | $1B | 0.03% |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $925.8M | 1.27% |
| CITADEL ADVISORS LLC | 2026-06-30 | $165.1M | 0.02% |
| Bridgewater Associates, LP | 2026-06-30 | $60.3M | 0.25% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $6.8M | 0.00% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$661.29
Target range
$368.00 – $728.00
Implied upside
12.56%
Strong buy
3
Buy
8
Hold
3
Sell
1
Strong sell
0
Advertisement